---
title: "B7-33"
canonical_url: https://peptidelibrary.app/library/b7-33
description: "Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# B7-33

B7-33 (also called Single-chain relaxin-2 analog or RXFP1 agonist peptide) is a relaxin-2 analog in the RXFP1 agonist class. B7-33 is a single-chain minimised analog of human relaxin-2, engineered to retain receptor activity in a much smaller and more synthetically tractable molecule than the two-chain native hormone.

Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved.

Also known as: Single-chain relaxin-2 analog, RXFP1 agonist peptide.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Relaxin-2 analog / research
- Mechanism class: RXFP1 agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

B7-33 is a single-chain minimised analog of human relaxin-2, engineered to retain receptor activity in a much smaller and more synthetically tractable molecule than the two-chain native hormone. It activates RXFP1, a G protein-coupled receptor expressed on vascular smooth muscle, endothelium and fibroblasts. A notable feature reported for B7-33 is biased signalling: it favours the ERK1/2 pathway over the cyclic AMP pathway that native relaxin also engages, which has been proposed to underlie antifibrotic activity with less of the vasodilatory response. In cardiac and renal models this manifests as reduced collagen deposition and matrix remodelling. It is preclinical with no human data.

Targets: RXFP1 (relaxin family peptide receptor 1).

Origin: Engineered single-chain human relaxin-2 analog.

## Properties

- Molecular formula: Synthetic single-chain peptide (≈5 kDa)
- Molecular weight: ~5 kDa
- Half-life: Short; stabilized vs native relaxin-2

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 2
- Latest source: 2023

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother. 2023. 2023. Preclinical: animal or lab study. Population: Adult male mice. Less heart fibrosis, inflammation and cardiomyocyte enlargement, similar to relaxin. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/36753958/)
2. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. J Am Heart Assoc. 2020. 2020. Preclinical: in vitro (cells or tissue). Population: Adult male mice. Smaller infarct (22% versus 45%) and better preserved heart function than vehicle. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/32295457/)

## Safety

Side effects: No established human dose; Hypotension theoretical.

Risks: Research-only; Not a substitute for serelaxin programs.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

B7-33 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is B7-33?

Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved.

### How does B7-33 work?

B7-33 is a single-chain minimised analog of human relaxin-2, engineered to retain receptor activity in a much smaller and more synthetically tractable molecule than the two-chain native hormone. It activates RXFP1, a G protein-coupled receptor expressed on vascular smooth muscle, endothelium and fibroblasts.

### Is B7-33 FDA approved?

No. B7-33 is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### What is the half-life of B7-33?

Reported half-life for B7-33 is Short; stabilized vs native relaxin-2. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

## References

- [The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy — Biomed Pharmacother, 2023](https://pubmed.ncbi.nlm.nih.gov/36753958/)
- [B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice — J Am Heart Assoc, 2020](https://pubmed.ncbi.nlm.nih.gov/32295457/)
- [Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation — ACS Appl Mater Interfaces, 2019](https://pubmed.ncbi.nlm.nih.gov/31713411/)
- [B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Eur J Pharmacol, 2017](https://pubmed.ncbi.nlm.nih.gov/28478069/)
- [Single chain peptide agonists of relaxin receptors — Mol Cell Endocrinol, 2019](https://pubmed.ncbi.nlm.nih.gov/30641102/)
